Impedimed Limited · ASX:IPD
Impedimed — HealthInvest September 2024
16 slides from Impedimed's conference presentation, Sep 18, 2024
Slide 1: Impedimed Limited
Impedimed Limited Dr Parmjot Bains, CEO & Managing Director HealthInvest, September 2024 Approved for release by Dr Parmjot Bains, CEO/MD Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance,
Slide 3: ImpediMed: Leaders in the BIS market
1 ImpediMed Leaders in the BIS market 3
Slide 4: SOZO: Digital Health Platform with Multiple FDA Cleared Applications
SOZO®: Digital Health Platform with Multiple FDA Cleared Applications with primary focus on L-Dex® A single SOZO One device, measurement provides: multiple FDA cleared applications • L-Dex® lymphoedema analysis • Lymphoedema – • HF-Dex® heart failure analysis FDA clearance, CE Mark • Body CompTM • H
Slide 5: Improving Survivorship for Breast Cancer Patients
Improving Survivorship for Breast Cancer Patients Preventing Breast Cancer- Related Lymphedema 290k 1 in 5 82% Newly diagnosed US breast Breast cancer patients will Breast cancer patients are at risk 92% Of patients did not progress to cancer patients every year1 develop lymphedema2 of arm lymphedem
Slide 6: ImpediMed's Bioimpedance Spectroscopy (BIS) Technology for Early Detection of Breast Cancer Related Lymphoedema
ImpediMed’s Bioimpedance Spectroscopy (BIS) Technology for Early Detection of Breast Cancer Related Lymphoedema enables Early, Objective & Fast Detection Current Standard of Care Bioimpedance Spectroscopy (BIS) – FDA-cleared, Clinically Validated, Subjective or Time-Consuming Guideline Supported, Re
Slide 7: BIS reimbursement in the US drives significant TAM
BIS reimbursement in the US for use by multiple providers across lymphedema treatment journey drives significant TAM Market opportunity for all at-risk cancers is significant and estimated at up to A$2bn of which, breast cancer- related lymphoedema estimated at 35% of total. Economics of market driv
Slide 8: SAAS Business driven by our US Market
2 SAAS Business driven by our US Market 8
Slide 9: Core business revenue and ARR improving
Core business revenue and ARR improving FY24 Full-Year Results Total SOZO Core SOZO Core Number of patient revenue1 Business2 revenue Business ARR tests conducted $10.3 million $9.7 million $11.0 million 250,000 9% vs FY23 due to 14% vs FY23 18% vs FY23 18% vs FY23 AZ trial cessation # SOZO units SO
Slide 10: ImpediMed is a SAAS business, with 50% of installed base, and 90% revenues in the US
ImpediMed is a SAAS business, with 50% of installed base, and 90% revenues in the US Global revenue by category Global revenue by geography Global Installed Base Units 1,083 1,041 997 933 11.3 11.3 10.6 10.3 10.6 10.3 513 494 2.0 0.1 2.0 0.1 469 0.5 0.9 444 3.3 0.8 3.3 1.0 0.7 1.1 A $ millions A $ m
Slide 11: Drivers of Core Business growth: ARR and patient tests increasing
Drivers of Core Business growth: ARR and patient tests increasing SOZO Core Business Patient Tests Annual Recurring Revenue1 Thousand tests A$ millions 22% 24% 3-year CAGR2 3-year CAGR2 11.0 10.1 9.3 8.2 7.3 154 6.7 6.1 126 92 70 40 17 85 96 62 72 32 47 8 2 FY21 FY22 FY22 FY23 FY23 FY24 FY24 FY18 FY
Slide 12: We are gaining momentum with a return to growth in TCV
We are gaining momentum with a return to growth in TCV SOZO Core Business Quarterly Total Contract Value (TCV1) 3.8 3.5 3.4 3.2 2.8 Focus on commercial execution 2.2 2.2 with urgency A$ millions 1.6 Gaining momentum FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY24 Q1 FY24 Q2 FY24 Q3 FY24 Q4 1.Total Contracted V
Slide 13: New team and strategy is now well set
3 New team and strategy is now well set 13
Slide 14: Building a sustainable business
Building a sustainable business New Executive Team and new Board Expanded commercial focus on lead generation for targeted US BCRL customers Prioritize key US states – high reimbursement, high population More efficient cost management Building a pathway to future growth
Slide 15: Immediate priority is focused sales, marketing and clinical execution in BCRL
Immediate priority is focused sales, marketing and clinical execution in BCRL, with 2-year strategy looking at adjacent markets ImpediMed 12-Month Priorities Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-c
Slide 16: impedimed
impedimed’